<DOC>
	<DOCNO>NCT02417961</DOCNO>
	<brief_summary>The purpose study assess functionality , performance , reliability accessorized pre-filled syringe ( APFS ) benralizumab administer subcutaneously ( SC ) at-home set report patient caregiver , confirm safety clinical benefit benralizumab administration asthma patient severe asthma .</brief_summary>
	<brief_title>Study Assess Functionality , Reliability , Performance Pre-filled Syringe With Benralizumab Administered Home</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion Written inform consent study participation must obtain prior study related procedure perform accord international guideline and/or applicable European Union ( EU ) guideline Male female patient age 18 75 year age time Visit 1 Patient caregiver must willing able selfadminister IP ( Investigational product ) . Caregiver must age consent old time Visit 1 , applicable Weight ≥40 kg Evidence asthma document either : Airway reversibility ( FEV1 ≥12 % 200 ml ) demonstrate Visit 1 2 OR document previous 12 month OR ; Airflow variability FEV1 ≥20 % pulmonary function test document 12 month prior V2 OR ; Airflow variability show &gt; 20 % diurnal variability peak flow observe patient 's asthma action plan Documented history current treatment ICS ( Inhaled corticosteroid ) LABA ( Longacting β2 agonist ) . The ICS LABA part combination product give separate inhaler . The ICS dose must great equal 500 μg/day fluticasone propionate dry powder formulation equivalent daily . For ICS/LABA combination preparation , mid highstrength maintenance dose approved local country meet ICS criterion . Additional asthma controller medication ( e.g. , LTRAs ( Leukotriene receptor antagonist ) , tiotropium , theophylline , oral corticosteroid ) allow Morning prebronchodilator ( preBD ) FEV1 &gt; 50 % predict Visit 1 Visit 2 Not well control asthma document either : An ACQ6 ( Asthma Control Questionnaire 6 ) ≥1.5 OR ; A peak flow 6080 % predict OR ; An exacerbation , one , require oral systemic corticosteroid previous year OR ; Any one following assessed patient recall previous 24 week : Asthma symptom &gt; 2 days/week ; OR / Nighttime awakening 1 more/week ; OR / Short act beta2agonist use symptom control ( prevention exercise induce asthma ) &gt; 2 days/week Exclusion criterion : Clinically important pulmonary disease asthma ( eg , active lung infection , COPD ( Chronic obstructive pulmonary disease ) , bronchiectasis , pulmonary fibrosis , cystic fibrosis , hypoventilation syndrome associate obesity , lung cancer , alpha 1 antitrypsin deficiency , primary ciliary dyskinesia ) ever diagnose pulmonary systemic disease , asthma , associate elevated peripheral eosinophil count ( eg , allergic bronchopulmonary aspergillosis/mycosis , ChurgStrauss syndrome , hypereosinophilic syndrome ) Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , hematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety patient throughout study ; Influence finding study interpretation ; Impede patient 's ability complete entire duration study Known history allergy reaction IP formulation History anaphylaxis biologic therapy History GuillainBarré syndrome A helminth parasitic infection diagnose within 24 week prior date informed consent obtain treat , fail respond standard care therapy Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior date informed consent obtain screening period Any clinically significant abnormal finding physical examination , vital sign , hematology , clinical chemistry , urinalysis screening period , opinion Investigator , may put patient risk his/her participation study , may influence result study , patient 's ability complete entire duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Asthma ,</keyword>
	<keyword>Bronchial Diseases ,</keyword>
	<keyword>Respiratory Tract Diseases ,</keyword>
	<keyword>Lung Diseases ,</keyword>
	<keyword>Obstructive Lung Diseases ,</keyword>
	<keyword>Benralizumab</keyword>
</DOC>